医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Neurotez Signs Exclusive Licensing Agreement with GCA Therapeutics to Develop Leptin Derivatives for the Treatment of Alzheimer’s Disease in Mainland China

2014年05月21日 PM09:45
このエントリーをはてなブックマークに追加


 

BRIDGEWATER, N.J.

Neurotez, Inc. today announced the execution of an exclusive license agreement covering its Leptin derivatives (Leptin Products), for the treatment of Alzheimer’s disease (AD) and other cognitive disorders, with GCA Therapeutics, Ltd. (GCAT). The exclusive license grants GCAT the right to clinically develop and commercialize Leptin Products in mainland China, exclusive of Hong Kong, and Taiwan. A version of Leptin has recently been approved in the USA for treating generalized lipodystrophy and in Japan for lipodystrophy.

Under the terms of the agreement, GCAT will assume all development and regulatory responsibility and associated costs for Leptin Products in China, and Neurotez will be eligible to receive gross sales milestones up to US$102.5 million as well as royalties on gross sales. The exclusive license also has certain minimum annual sales thresholds following first commercial sales in mainland China.

“GCAT has a demonstrated track record of successfully developing therapeutics for the large China/Asian markets, and we are delighted to enter this license agreement with them for China,” said Nikolaos Tezapsidis, President and Chief Executive Officer of Neurotez, Inc. “This license is the first of what we anticipate to be a series of agreements designed to allow our program to reach the large global market of patients with Alzheimer’s disease.”

Dr. Mark Tang, Chairman of GCAT, said, “We are very excited about the potential benefits of this product for Alzheimer’s disease patients, especially given the potential market size in China, where AD is becoming increasingly prevalent and remains an unmet medical need. We look forward to a productive and profitable collaboration between Neurotez and GCAT.”

About Neurotez, Inc.

Neurotez Inc. (www.neurotez.com) is a privately held Delaware corporation, based in New Jersey, developing recombinant human Leptin as a hormone replacement therapy for Alzheimer’s disease (AD), and as a preventative for those who are at risk.

About GCAT

Founded by U.S. trained Chinese professionals and industry veterans in both finance and pharmaceuticals and based in New Jersey, GCA Therapeutics, Ltd (GCAT, www.gcatherapeutics.com) is focusing on licensing technologies and products to be developed and marketed in China.

CONTACT

Neurotez, Inc.
Nikolaos Tezapsidis, 908-998-1340
ntezapsidis@neurotez.com
or
GCA
Therapeutics, Ltd.
Mark Tang, PhD, MBA, 201-882-2591
cmtang@gcatherapeutics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表